|
Lenacapavir: new drug for the treatment of multidrug-resistant HIV infection |
|---|---|
| รหัสดีโอไอ | |
| Creator | Chatchai Wararit |
| Title | Lenacapavir: new drug for the treatment of multidrug-resistant HIV infection |
| Publisher | Faculty of Pharmaceutical Sciences KKU MSU UBU |
| Publication Year | 2567 |
| Journal Title | Isan Journal of Pharmaceutical Sciences |
| Journal Vol. | 20 |
| Journal No. | 2 |
| Page no. | 1-11 |
| Keyword | HIV, Antiretroviral drug, lenacapavir, multidrug resistant |
| URL Website | https://tci-thaijo.org/index.php/IJPS |
| Website title | Isan Journal of Pharmaceutical Sciences, IJPS |
| ISSN | 19050852 |
| Abstract | HIV infection is currently still an epidemic disease which affect quality of life and life expectancy. Currently, there were reports of the antiretroviral drug resistance incidence. Lenacapavir is a novel drug in capsid inhibitors approved for treatment multidrug-resistant HIV infection in combination with optimized background regimen. Lenacapavir is available as an oral and subcutaneous injection used for initiation treatment. Subcutaneous injection drug has a half-life of 8-12 weeks used for maintenance treatment and administered via subcutaneous every 6 months. Clinical trial data supports efficacy for viral suppression and increase the CD4+ cell count. The most common adverse reactions is injection site reactions. Lenacapavir is substrate of cytochrome P450 (CYP) 3A enzymes, P-glycoprotein (P-gp), uridine diphosphate glucuronosyltransferases 1A1 (UGT1A1) and moderate inhibitor of CYP3A. Drug-drug interactions should be concerned when use lenacapavir in combination with other drugs. For pediatric and elderly populations, efficacy and safety data are limited. |
